首页> 外文期刊>Hypertension research: Official journal of the Japanese Society of Hypertension >Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.
【24h】

Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.

机译:替米沙坦和氨氯地平对患有轻度肾功能不全的慢性肾脏病高血压患者的肾脏和血管保护作用的比较。

获取原文
获取原文并翻译 | 示例
           

摘要

The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency. Thirty hypertensive CKD patients were randomly assigned to receive telmisartan 40 mg (n = 15) or amlodipine 5 mg (n = 15) once daily for 12 months. Changes in blood pressure, serum creatinine, 24-h creatinine clearance (Ccr), proteinuria, brachial-ankle pulse wave velocity (baPWV), intima-media thickness (IMT), plasma interleukin-6 (IL-6), plasma matrix metalloproteinase (MMP)-9 and lipid profiles were monitored in all patients. Before treatment, there were no significant differences in these parameters between the telmisartan and amlodipine groups. Over the 12 month observation period, blood pressure decreased equally in both groups. However, serum creatinine, proteinuria, baPWV, IMT, plasma levels of IL-6 and MMP-9 and total cholesterol decreased and 24-h Ccr increased more strikingly in the telmisartan group than the amlodipine group. These data suggest that telmisartan is more effective than amlodipine for protecting renovascular functions, and potentially for ameliorating atherosclerosis, in hypertensive CKD patients with moderate renal insufficiency.
机译:本研究旨在比较替米沙坦和氨氯地平对未治疗的中度肾功能不全的高血压慢性肾脏病(CKD)患者的肾脏和血管保护作用。 30名高血压CKD患者被随机分配接受替米沙坦40 mg(n = 15)或氨氯地平5 mg(n = 15)每天一次,持续12个月。血压,血清肌酐,24小时肌酐清除率(Ccr),蛋白尿,臂腕踝脉搏波速度(baPWV),内膜中层厚度(IMT),血浆白介素6(IL-6),血浆基质金属蛋白酶的变化监测所有患者的(MMP)-9和血脂情况。在治疗前,替米沙坦和氨氯地平组的这些参数没有显着差异。在12个月的观察期内,两组血压均下降。但是,替米沙坦组的血清肌酐,蛋白尿,baPWV,IMT,IL-6和MMP-9血浆水平以及总胆固醇降低,而24小时Ccr显着高于氨氯地平组。这些数据表明,在患有中度肾功能不全的高血压CKD患者中,替米沙坦比氨氯地平更有效地保护肾血管功能,并可能改善动脉粥样硬化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号